SECAUCUS, N.J. — Quest Diagnostics reported first-quarter 2026 results on April 21, 2026, announcing net income of about $251–$252 million, GAAP EPS of $2.24 and adjusted EPS of $2.50 on revenue near $2.9 billion. The company also updated full-year adjusted diluted EPS guidance to $10.63–$10.83 and net revenue guidance to $11.78–$11.90 billion. The results topped Zacks consensus estimates for both earnings and revenue on Tuesday, and management cited roughly 9% organic revenue growth in the quarter when raising guidance. In pre-market trading this week, Quest shares were reported up about 2.39 percent, and analysts and investors will monitor second-quarter trends and execution against the revised 2026 outlook.
Prepared by Christopher Adams and reviewed by editorial team.
Quest Diagnostics 强劲的第一季度业绩可能会影响您的钱包。如果您持有股票,您的投资很可能正在增长。如果您正在考虑投资,这可能是一家值得关注的公司。请检查您的投资组合或咨询您的财务顾问。
Quest 正在展现稳健的增长并超出预期,这对股东和潜在投资者来说是个好消息。他们修订后的 2026 年展望可能意味着持续增长。如果您认识考虑投资的人,值得转发。
股东和公司管理层受益于超出预期的第一季度业绩和上调的2026年业绩指引,这支撑了近期股价的上涨。
竞争性诊断实验室和短期市场空头面临着 Quest Diagnostics 强劲业绩和上调全年业绩指引的压力。
No left-leaning sources found for this story.
No right-leaning sources found for this story.
Comments